Oncology care sees visits. Toxicity unfolds between them.
ONCOTrack is medical device software in development, designed to structure toxicity monitoring around treatment context and the patient’s course across cycles, creating a longitudinal view of what happens between oncology visits.
Not CE-marked · not clinically validated
A clinic visit is a snapshot. Toxicity is a trajectory.
ONCOTrack is being developed to turn that interval into structured longitudinal clinical information.
Monitoring should follow the treatment and the patient, not just the questionnaire.
Monitoring designed to reflect treatment context rather than apply a uniform symptom framework across patients.
Each treatment cycle contributes to an evolving clinical picture rather than a series of isolated observations.
The patient’s previous toxicity and treatment course become relevant context as treatment continues.
The longitudinal record becomes more informative over time.
ONCOTrack begins with structured toxicity monitoring, but repeated treatment cycles can create a progressively richer longitudinal picture of treatment context, toxicity patterns and clinical evolution.
Long-term research may explore whether such longitudinal information can support clinically validated forecasting of individual toxicity trajectories and clinically relevant deterioration.
- Current product
Longitudinal toxicity monitoring
- Potential over time
Increasingly informative longitudinal clinical context
- Future R&D · not a current capability
Clinically validated toxicity forecasting
Predictive capabilities are a future R&D direction and would require dedicated model development and clinical validation before clinical use.
Any secondary research use of patient data would require an appropriate legal basis, ethics review where applicable, and agreed data governance arrangements with participating care providers.
Built beyond the concept stage.
Structured patient reporting
Clinical overview
A structured view of reported toxicity across the treatment course.
Longitudinal review
Clinical information organised across cycles rather than as isolated reports.
Additional product information and a private demonstration are available for qualified clinical and investment discussions.
The next milestone is clinical workflow, not another prototype.
How patients and clinical teams interact with the product.
How structured monitoring fits into everyday oncology practice.
Whether the intended longitudinal toxicity information can be captured consistently in the clinical setting.
Oncology expertise. Regulated software execution.
Wiem Chaabane, PhD
Founder & CEO
Molecular oncology researcher with more than 15 years of experience in cancer research, including five years at Karolinska Institutet. Leads clinical strategy, product development, regulatory planning and partnerships.
Oncology · Clinical strategy · ProductAndrei Kluger
CTOTechnical architecture and regulated software development. Former CTO and co-founder of re.flex, which he helped take from prototype to inclusion in Germany’s DiGA directory.
Technology · Regulated softwareONCOTrack is being developed within the Swedish health innovation ecosystem.
Evaluate ONCOTrack in clinical workflow.
For Swedish oncology teams interested in structured toxicity monitoring between treatment cycles.
Discuss a clinical pilotExplore the platform behind the product.
Additional product information, regulatory pathway, clinical development plan and long-term technology roadmap are available for qualified discussions.
Request investor information